Recursion Pharmaceuticals reported mixed Q2 results, with revenue declining to $7.67 million and a narrowed net loss of $131.01 million. The company achieved key milestones in its AI-driven drug ...
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results